WO2003041700A1 - Storage stable thyroxine active drug formulations - Google Patents
Storage stable thyroxine active drug formulations Download PDFInfo
- Publication number
- WO2003041700A1 WO2003041700A1 PCT/US2002/036266 US0236266W WO03041700A1 WO 2003041700 A1 WO2003041700 A1 WO 2003041700A1 US 0236266 W US0236266 W US 0236266W WO 03041700 A1 WO03041700 A1 WO 03041700A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- weight
- amount
- sucrose
- mannitol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the invention relates generally to the field of medicinal formulations, and more particularly to methods of preparing storage stable pharmaceutical compositions in unit dosage form of levothyroxine sodium with increased shelf life and compositions made by these methods.
- Thyroxine active drugs are known for both therapeutic and prophylactic treatment of thyroid disorders.
- levothyroxine sodium is prescribed for thyroid hormone replacement therapy in cases of reduced or absent thyroid function in e.g., ailments such as myxedema, cretinism and obesity.
- Levothyroxine sodium is quite unstable, hygroscopic and degrades rapidly when subjected to high humidity, light or high temperature. See, for example, Won, Pharm. Res. 9 (1 ): 131-137, 1992.
- Formulations containing levothyroxine sodium have been known in the art since the late 1950s. There have been recent attempts to develop more stable dosage formulations of levothyroxine sodium.
- U.S. Pat. No. 5,635,209 discloses levothyroxine sodium in combination with potassium iodide as part of a stabilizing excipient.
- levothyroxine sodium was first mixed with microcrystalline cellulose, and then added to a dried granulation of potassium iodide and microcrystalline cellulose. The formulation purportedly provided increased active drug potency over a three month period in comparison to then commercially available formulations.
- United States Patent No. 5,225,204 discloses a complex of levothyroxine sodium and a cellulose, polyvinylpyrrolidone or Poloxamer.
- the formulation may be prepared by dissolving the drug complex in a polar organic solvent, adding a cellulose carrier to the liquid, and drying the resulting mixture to obtain a complex of levothyroxine sodium and polyvinylpyrrolidone or Poloxamer adsorbed on the cellulose carrier.
- the deposition onto cellulose may have resulted in some increased stability due to improved content uniformity. Tests of such combinations yielded stability results at best equal to commercially available preparations such as those described in U.S. Patent No. 5,955,105, and in some cases substantially worse.
- the inventors of this stabilized composition teach one of skill in the art away from the use of carbohydrates in levothyroxine sodium formulations, stating that instability of the dosage form was the result of an interaction between the active drug substance and carbohydrate excipients.
- the inventors of United States Patent No. 5,955,105 also teach that the instability of thyroxine drugs is due to an interaction between the drug and the excipient.
- These inventors incorporated into the formulation a soluble glucose polymer designed to eliminate the interaction between the drug and other excipients contained in the final blend.
- the present invention relates to methods and compositions which increase the stability of levothyroxine sodium and other thyroxine active drugs. This invention prevents the decreases in effective dosage which plague prior art thyroxine active drug formulations and substantially increases shelf life.
- compositions include an active thyroxine drug with an alditol and a saccharide.
- Other optional ingredients in the composition include but are not limited to pharmaceutically acceptable excipients such as cellulose polymers or carbohydrates, disintegrants, lubricants and glidants.
- the present invention provides a storage stable oral pharmaceutical composition which comprises a therapeutically effective amount of a thyroxine active drug and stabilizing amounts of an alditol and a saccharide.
- the thyroxine active drug is levothyroxine sodium
- the alditol is mannitol
- the saccharide is sucrose.
- compositions of the invention comprise at least one further pharmaceutical excipient, such as a carbohydrate, a starch or a modified starch, for example microcrystalline cellulose.
- this invention provides storage stable oral pharmaceutical compositions in unit dosage form comprising the compositions discussed above, and particularly a storage stable oral dosage form composition which comprises levothyroxine sodium, mannitol, sucrose, and optionally further comprises microcrystalline cellulose, polyvinylpyrrolidone, crospovidone, magnesium stearate, sodium lauryl sulfate, and colloidal silicon dioxide.
- the invention preferably provides such storage stable oral dosage forms in the form of tablets.
- a preferred embodiment of the invention encompasses a storage stable oral pharmaceutical composition which comprises a therapeutically effective amount of levothyroxine sodium; about 58% by weight mannitol; about 14% by weight sucrose; about 25% by weight microcrystalline cellulose; about 1.5% by weight polyvinylpyrrolidone; about 1.4% by weight magnesium stearate; about 0.3% by weight colloidal silicon dioxide; and about 0.1% by weight sodium lauryl sulfate.
- Another preferred embodiment of the invention encompasses a storage stable oral pharmaceutical composition which comprises a therapeutically effective amount of levothyroxine sodium; about 39% by weight mannitol; about 23% by weight sucrose; about 28% by weight microcrystalline cellulose; about 1.5% by weight polyvinylpyrrolidone; about 6% by weight crospovidone; about 2% by weight magnesium stearate; about 0.3% by weight colloidal silicon dioxide; and about 0.1% by weight sodium lauryl sulfate.
- the present invention relates to storage stable granulation intermediates and oral pharmaceutical compositions in unit dosage form of a thyroxine active drug and methods by which they are produced.
- the methods involve a granulation intermediate containing the thyroxine active drug substance, an alditol, and a monosaccharide or disaccharide to provide a formulation with an increase of stability of both the granulation intermediates and the final oral dosage forms prepared from these granulation intermediates.
- the present invention provides a stable dosage form in which the dosage of thyroxine active drug is maintained at a predictable level for a longer period of time.
- Formulations of levothyroxine with greatly increased resistance to degradation can be produced by providing excipients which reduce or eliminate degradation of the active substance.
- the prior art indicates that reaction between levothyroxine sodium and certain carbohydrate, monosaccharide or disaccharide excipients is responsible for the poor stability of the drug
- the present inventive formulation achieves surprisingly stable levothyroxine dosage forms using these previously disfavored excipients. Additionally, preferred formulations are maintained at a pH of less than about 10.
- the methods and formulations of this invention take advantage of the discovery that including an alditol and a saccharide results in a surprisingly stable levothyroxine sodium composition.
- This invention can be used to produce stable formulations of any natural or synthetic thyroid hormone replacement drug. Therefore, although the following description and example refer to compositions and methods using levothyroxine sodium, the invention is understood to encompass other thyroid hormone medications of the general formula
- R x and R 3 may be the same or different and are selected from hydrogen; halogen; alkyl; aryl; cycloalkyl; heterocycloalkyl; amide; alcohol; acid; ester; ether; acyl; alkenyl; and alkynyl; wherein R 2 is
- R 4 and R 5 may be the same or different and are selected from hydrogen; halogen; alkyl; aryl; cycloalkyl; heterocycloalkyl; amide; alcohol; acid; ester; ether; acyl; alkenyl; and alkynyl.
- the medication can be in the form of a free acid, a free base, an organic salt, an inorganic salt, or a hydrate.
- Liothyronine is an example of a drug encompassed by the above-mentioned general formula.
- stabilized pharmaceutical compositions are produced by blending the active ingredient with an alditol and a saccharide such as a monosaccharide or disaccharide to form a granulation intermediate. Addition of any additional pharmaceutical excipients, diluents or granulation aids is optional. Generally, further pharmaceutical excipients are added to produce final oral dosage forms such as tablets or capsules . [00017] Formulations according to this invention are made according to the following general steps. Those of skill in the art are aware of equivalent methods and variations which produce the same general result. Therefore, the general instructions and the example which follows should not be considered to be strictly limiting.
- the active thyroxine ingredient for example, levothyroxine sodium
- an alditol and/or a saccharide to form a pre-blend for ease of handling.
- Preferred granulation intermediates are produced by making a wet granulation of the active ingredient with an alditol such as mannitol, a saccharide such as sucrose and a granulation aid such as microcrystalline cellulose.
- the active ingredient is blended first with the alditol, sucrose is then added and the material is blended again.
- microcrystalline cellulose also polyvinylpyrrolidone as binder
- the microcrystalline cellulose or other diluent functions as a granulation aid and compression enhancer (for tablet or capsule formulations) and not as a specific carrier for the thyroxine active drug.
- the wet granulation is dried, milled and optionally further blended.
- the granulation intermediate then may be stored or directly mixed with further ingredients to form a composition suitable for compression into tablets, filling into capsules or dissolved or suspended to form a liquid dosage form.
- Alditols which are suitable for use in this invention are those whose presence stabilizes the thyroxine drug. Alditols are widely known in the art. Preferred alditols include, but are not limited to, one or more of the following: mannitol, sorbitol, maltitol and xylitol.
- the alditol is mannitol.
- Saccharides for use with this invention are those that stabilize the thyroxine drug. Such saccharides include one or more monosaccharides, disaccharides and oligosaccharides composed of 2-10 monosaccharides.
- Monosaccharides, also known as reducing sugars, which may be used in the present invention generally include aldoses, hemiacetals and cyclic hemiacetals.
- Disaccharides are generally defined as two monosaccharide units joined together by a glycoside linkage.
- Oligosaccharides are generally defined as carbohydrates that hydrolyze to yield 2 to 10 molecules of a monosaccharide.
- Preferred monosaccharides, disaccharides, and oligosaccharides include, but are not limited to: sucrose, maltose, cellobiose, lactose, trehalose, glucose, fructose, galactose, ribose or deoxyribose.
- the saccharide is a monosaccharide or a disaccharide, and more preferably is a disaccharide. The most preferred saccharide is sucrose .
- compositions of this invention may be prepared for administration orally, rectally, vaginally, transmucosally, transdermally, parenterally, subcutaneously, and intramuscularly.
- Pharmaceutically acceptable excipients which are suitable for use in formulations for these methods of administration are known to those of skill in the art and may be included in formulations according to this invention.
- excipients contemplated for use in the inventive formulations may include, but are not limited to adjuvants; preservatives; buffers; fillers, extenders, carriers, binders and diluents; glidants and lubricants; surfactants, wetting agents and surface active agents; suspending agents and solvents.
- compositions such as dyes and colorants, sweeteners, flavorings, perfuming agents and taste-masking ingredients also may be included in formulations according to this invention.
- Any pharmaceutically acceptable excipient such as ingredients to aid in processing or to improve taste or appearance are contemplated for use with these formulations. Further excipients may be included according to the judgment of the pharmaceutical scientist formulating the medicament.
- other active ingredients may be included to produce a dual or multiple ingredient medication.
- Exemplary surfactants and surface active agents may be selected from known pharmaceutical excipients such as, for example, gelatin, casein, lecithin, gum acacia, stearic acid or other fatty acids, benzalkonium chloride, calcium stearate, glyceryl monostearate or other fatty acid salts, polyethylene glycols, silicon dioxide, methylcelluloses or carboxymethylcelluloses, sodium stearyl fumarate, magnesium stearate, alginate, or any other surface modifying compounds known in the art.
- Compounds which function as wetting agents such as, for example, pharmaceutically acceptable detergents and cetyl alcohols also are contemplated for use with the inventive formulations .
- Lubricants such as talc, calcium stearate, sodium stearyl fumarate, stearic acid, magnesium stearate, solid polyethylene glycols and cocoa butter are useful with the inventive formulations, as are one or more binders, fillers or extenders such as starches, lactose or other sugars, polyvinylpyrrolidone, sodium citrate, dicalcium phosphate and other alkaline inorganic salts, carboxylmethylcellulose and other cellulose polymers, alginates, gelatins, microcrystalline cellulose, sorbitol, sodium chloride, chitosan, hydrogenated vegetable oil, kaolin, glycerol palmitostearate, magnesium carbonate, and calcium carbonate.
- binders such as starches, lactose or other sugars, polyvinylpyrrolidone, sodium citrate, dicalcium phosphate and other alkaline inorganic salts, carboxylmethylcellulose and other cellulose polymers, alginates, gelatins, micro
- Solid dosage forms which may be prepared according to this invention can include tablets, capsules, rectal or vaginal suppositories, pills, dragees, lozenges, granules, beads, microspheres, pellets and powders, or any combination thereof. Formulations also may be prepared in the form of solutions, suspensions, emulsions, syrups and elixirs. These liquid dosage forms may include liquid diluents in addition to the solid ingredients discussed above.
- Such diluents may include, but are not limited to solvents, solubilizing agents, suspending agents and emulsifiers such as water or saline solutions, ethanol and other pharmaceutically acceptable alcohols; ethyl carbonate; ethyl acetate; propylene glycol; dimethyl formamide; pharmaceutically acceptable oils such as cottonseed, corn, olive, castor and sesame; fatty acid esters of sorbitan; polyoxyethylene sorbitol; and agar-agar.
- solvents solubilizing agents, suspending agents and emulsifiers
- emulsifiers such as water or saline solutions, ethanol and other pharmaceutically acceptable alcohols
- ethyl carbonate such as ethyl acetate
- propylene glycol dimethyl formamide
- pharmaceutically acceptable oils such as cottonseed, corn, olive, castor and sesame
- fatty acid esters of sorbitan such as cottonseed, corn, olive, castor
- the formulations of this invention may be used for any convenient dosage amount of the active ingredient.
- the level of the active ingredient may be increased or decreased according to the judgment of the physician, pharmacist, pharmaceutical scientist or other person of skill in the art.
- the amount of the remaining non-active ingredients can be adjusted as needed.
- the amount of alditol is adjusted to compensate for changes in the amount of active ingredient.
- the preferred active ingredient in the formulations of this invention is levothyroxine sodium.
- Therapeutically effective dosage amounts for this drug generally range from about 0.1 ⁇ g to about 5000 ⁇ g and are most preferably from about 25 ⁇ g to about 300 ⁇ g. Exemplary dosages therefore include, but are not limited to 20 ⁇ g, 25 ⁇ g, 50 ⁇ g, 75 ⁇ g, 88 ⁇ g, 100 ⁇ g, 112 ⁇ g, 125 ⁇ g, 150 ⁇ g, 175 ⁇ g, 200 ⁇ g and 300 ⁇ g.
- Preferred solid dosage forms prepared according to this invention contain the following compounds: levothyroxine sodium (active drug substance) ; mannitol; microcrystalline cellulose (diluent) ; polyvinylpyrrolidone (binder) ; sucrose; crospovidone (disintegrant) ; magnesium stearate (lubricant) ; sodium lauryl sulfate (surfactant) ; and colloidal silicon dioxide (glidant) .
- Formulations of thyroxine active drugs prepared according to this invention contain about 0.1 ⁇ g to about 5000 ⁇ g thyroxine active drug substance, preferably about 1 ⁇ g to about 1000 ⁇ g and most preferably about 25 ⁇ g to about 300 ⁇ g.
- Alditols should be present at from about 5% to about 90% (by weight) of the final formulation, preferably from about 15% to about 80% and most preferably from about 25% to about 70%.
- Filler such as carbohydrates (starch or cellulose polymer) , for example microcrystalline cellulose, generally should comprise from about 5% to about 90% by weight of the final formulations, preferably from about 15% to about 80% and most preferably from about 25% to about 70%.
- Final dosage forms generally contain from about 5% to about 70% saccharide, by weight, preferably from about 10% to about 60%, and most preferably from about 20% to about 40%.
- ingredients in the final dosage form may include a disintegrant, which if present, generally forms from about 2% to about 30% of the final formulation by weight, preferably from about 2% to about 15% and most preferably from about 3% to about 10%.
- Lubricants may be present in the final formulation at from about 0.1% to about 5% by weight, preferably from about 0.2% to about 3% and most preferably from about 0.5% to about 2.5%.
- Glidants may be present in final formulations according to this invention at from about 0.05% to about 2% by weight, preferably from about 0.075% to about 1% and most preferably from about 0.1% to about 0.5%.
- Surfactants may be present in final formulation according to this invention at from about 0.005% to about 1% by weight, preferably from about 0.01% to about 0.5% by weight, and most preferably from about 0.01% to about 0.2%.
- Binders may be present in final formulation according to this invention at from about 0.1% to about 10% by weight, preferably from about 0.5% to about 5% by weight, and most preferably from about 1% to about 3% by weight.
- compositions according to the invention may be stored in the form of powders, granulates, intermediates, suspensions, or solutions prior to addition of additional desired pharmaceutical excipients for the production of final dosage forms such as tablets or solid-filled capsules, or final liquid dosage forms such as solutions, syrups, suspensions, emulsions and the like.
- the mannitol and the levothyroxine sodium were blended for 10 minutes using conventional mixing equipment.
- the blended material, microcrystalline cellulose, and the sucrose were then passed through a hammer mill and the milled materials were blended for 15 minutes.
- the powders were granulated with a 15% w/w hydroalcoholic solution of polyvinylpyrrolidone. Additional water was added as needed for consistency of the granulation.
- the wet granulation mixture was dried in a fluidized bed dryer at 40°C until the moisture content was less then 4%.
- the dried granulation was sized by passing it through a hammer mill then blended for 5 minutes using conventional mixing equipment.
- colloidal silicon dioxide, the magnesium stearate/sodium lauryl sulfate (94/6), and the FD&C Yellow Aluminum Lake No. 6 lake were blended for 3 minutes and the mixture was passed through a #30 mesh screen.
- the microcrystalline cellulose and the mannitol were sized by screening and milling, respectively.
- the screened ingredients were then blended with the levothyroxine sodium granulation intermediate for 15 minutes until uniform.
- the mixture was compressed into tablets, each weighing approximately 130 mg, on a rotary tableting machine.
- Table 2 represents the stability data generated for storage of tablets made according to Example 1. These tablets were stored at 25, 40, and 50°C for 5 days at ambient humidity in 75 cc standard HDPE pharmaceutical containers. Samples of these tablets were analyzed for drug potency using an HPLC standard assay. Evaluation of the potency for these tablets demonstrates that the stabilized formulation of Example 1 yields a product which demonstrates good stability at all temperatures at or below 40°C.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/987,130 US6645526B2 (en) | 2001-11-13 | 2001-11-13 | Storage stable thyroxine active drug formulations and methods for their production |
US09/987,130 | 2001-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003041700A1 true WO2003041700A1 (en) | 2003-05-22 |
Family
ID=25533060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036266 WO2003041700A1 (en) | 2001-11-13 | 2002-11-13 | Storage stable thyroxine active drug formulations |
Country Status (2)
Country | Link |
---|---|
US (4) | US6645526B2 (en) |
WO (1) | WO2003041700A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2692340A1 (en) * | 2012-08-03 | 2014-02-05 | Verisfield (UK) Ltd. | Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof |
IT201700063186A1 (en) * | 2017-06-08 | 2018-12-08 | Trifarma S P A | PHARMACEUTICAL COMPOSITIONS OF LEVOTIROXINE SODIUM SALT |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
US8293272B2 (en) * | 2003-05-02 | 2012-10-23 | Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
EP1670449B1 (en) | 2003-09-15 | 2012-06-27 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use in angiogenesis |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
EP1786459B1 (en) * | 2004-07-26 | 2014-02-12 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition whit a botulinum neurotoxin |
PL1811987T3 (en) * | 2004-11-18 | 2008-08-29 | Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A | Dry powder comprising levothyroxine sodium administered via inhalator |
US20090022806A1 (en) * | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US20100209382A1 (en) | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
AU2006299645B2 (en) | 2005-09-30 | 2011-02-03 | Io Therapeutics, Llc | Treatment of cancer with specific RXR agonists |
EP1955698B1 (en) * | 2005-12-02 | 2013-10-30 | Mochida Pharmaceutical Co., Ltd. | Preventive/therapeutic agent for alzheimer's dementia |
AU2007353426A1 (en) * | 2006-12-22 | 2008-11-20 | Albany College Of Pharmacy And Health Sciences | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
JP5284967B2 (en) * | 2007-02-01 | 2013-09-11 | 武田薬品工業株式会社 | Tablet formulation that does not cause tableting problems |
WO2010075332A1 (en) * | 2008-12-23 | 2010-07-01 | Charitable Leadership Foundation | Small molecule ligands of the integrin rgd recognition site and methods of use |
US9180107B2 (en) * | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
CA2765792C (en) | 2009-06-17 | 2017-03-28 | Ordway Research Institute, Inc. | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US20110002966A1 (en) * | 2009-07-01 | 2011-01-06 | Alex Lovett | Vaginal Suppository System and Method |
US20120190748A1 (en) * | 2009-08-04 | 2012-07-26 | Haren Treasurer | Greater utility with thyroid hormone |
EP2627318B1 (en) | 2010-10-12 | 2017-08-16 | Merz Pharma GmbH & Co. KGaA | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
EP2750664A1 (en) | 2011-08-30 | 2014-07-09 | Fresenius Kabi USA, LLC | Levothyroxine formulations |
AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US9271951B2 (en) | 2012-12-21 | 2016-03-01 | Mylan Inc. | Levothyroxine formulation with acacia |
WO2014138603A1 (en) * | 2013-03-07 | 2014-09-12 | Amneal Pharmaceuticals, LLC | Stabilization of moisture-sensitive drugs |
US8779000B1 (en) * | 2013-07-20 | 2014-07-15 | Nilesh Parikh | Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production |
US9682045B2 (en) * | 2014-11-21 | 2017-06-20 | Cadila Healthcare Limited | Stable pharmaceutical compositions of thyroid hormone drug |
NZ741393A (en) | 2015-10-31 | 2018-11-30 | Io Therapeutics Inc | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones |
EP3368081A4 (en) * | 2015-10-31 | 2019-06-19 | IO Therapeutics, Inc. | Treatment of cancer with combinations of rxr agonists and thyroid hormones |
IL261669B2 (en) | 2016-03-10 | 2023-12-01 | Io Therapeutics Inc | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
AU2016396659B2 (en) | 2016-03-10 | 2019-02-14 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
WO2017214299A1 (en) | 2016-06-07 | 2017-12-14 | Nanopharmaceuticals, Llc | NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS |
US9782376B1 (en) | 2016-12-01 | 2017-10-10 | Fresenius Kabi Usa Llc | Levothyroxine liquid formulations |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US10231931B1 (en) | 2018-03-23 | 2019-03-19 | Genus Lifesciences Inc. | Thyroid hormone oral dosage forms and methods of using the same |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
PL3781126T3 (en) | 2018-04-16 | 2022-10-10 | Ioulia Tseti | A pharmaceutical dry powder composition for inhalation comprising a thyroid hormone |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
WO2023088976A1 (en) * | 2021-11-16 | 2023-05-25 | Tap Pharmaceuticals, Ag | Orodispersible levothyroxine compositions |
WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
US5635209A (en) | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
US5955105A (en) | 1995-11-14 | 1999-09-21 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
JP2002284679A (en) * | 2001-03-27 | 2002-10-03 | Teikoku Hormone Mfg Co Ltd | Stable solid preparation composition containing thyroid hormone |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415547A (en) | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
CH658188A5 (en) | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | STORAGE STABLE QUICK DISASSEMBLING PHARMACEUTICAL PRESSELS. |
US5200193A (en) | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
US5073380A (en) | 1987-07-27 | 1991-12-17 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US5004613A (en) | 1987-07-27 | 1991-04-02 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US4910023A (en) | 1988-06-09 | 1990-03-20 | Warner-Lambert Company | Drug in combination with flavor masking agent and method for making same |
US5330766A (en) | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5032405A (en) | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
NZ235876A (en) * | 1989-11-01 | 1992-06-25 | Mcneil Ppc Inc | Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
DE4220782A1 (en) | 1992-06-25 | 1994-01-05 | Basf Ag | Process for the preparation of solid pharmaceutical sustained release forms |
US5571840A (en) | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
IT1264696B1 (en) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED |
HU213407B (en) | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
GB9401891D0 (en) | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
GB9401892D0 (en) | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
MY115334A (en) | 1994-02-07 | 2003-05-31 | Shiseido Co Ltd | Method for inhibiting oxidation of oils and fats or fatty acids |
US5456851A (en) | 1994-04-07 | 1995-10-10 | Johnson & Johnson Consumer Products, Inc. | Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole |
ES2082723B1 (en) | 1994-07-20 | 1996-10-01 | Lilly Sa | PHARMACEUTICAL FORMULATION OF FLUOXETINE IN A DISPERSIBLE FORM. |
US5948438A (en) | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
IL139728A (en) | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
HUT75956A (en) * | 1995-11-29 | 1997-05-28 | Cyclolab | Pharmaceutical composition containing thyroxine |
IT1282650B1 (en) | 1996-02-19 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS |
US5800834A (en) | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US5951989A (en) | 1997-04-07 | 1999-09-14 | Heymann; Warren R. | Method for the treatment of dry skin |
FR2772615B1 (en) * | 1997-12-23 | 2002-06-14 | Lipha | MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES |
US6190696B1 (en) | 1998-06-08 | 2001-02-20 | Pieter J. Groenewoud | Stabilized thyroxine medications |
US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
US6399101B1 (en) | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
US20020077364A1 (en) * | 2000-07-06 | 2002-06-20 | Ramaswamy Murari | Thyroid hormone formulations |
US6855333B1 (en) | 2000-10-03 | 2005-02-15 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid thyroid drug formulations |
US6979462B1 (en) | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
US20030199588A1 (en) * | 2001-02-15 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions and methods |
JP2004525109A (en) | 2001-02-15 | 2004-08-19 | キング・ファーマシューティカルズ・インコーポレイティッド | Stabilized thyroid hormone pharmaceutical composition and method for producing the same |
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
WO2002067854A2 (en) | 2001-02-15 | 2002-09-06 | King Pharmaceuticals, Inc. | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
NZ511144A (en) | 2001-04-12 | 2004-01-30 | Invensys Energy Systems Nz Ltd | Low output noise switched mode power supply |
ITMI20011401A1 (en) * | 2001-07-02 | 2003-01-02 | Altergon Sa | PHARMACEUTICAL FORMULATIONS FOR THYROID HORMONES |
WO2003013441A2 (en) | 2001-08-10 | 2003-02-20 | King Pharmaceuticals, Inc. | Levothyroxine compositions and methods |
US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
US20030194436A1 (en) * | 2001-08-10 | 2003-10-16 | Franz Andrew G. | Immediate release pharmaceutical compositions |
US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
US20030199585A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G Andrew | Levothyroxine compositions and methods |
US20030185885A1 (en) * | 2001-08-10 | 2003-10-02 | Franz G. Andrew | Non-granulated levothyroxine pharmaceutical compositions |
US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
US20030195254A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
WO2003061557A2 (en) | 2001-08-14 | 2003-07-31 | King Pharmaceuticals, Inc. | Levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
US20030194437A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Cmax properties |
US20030180356A1 (en) | 2001-10-29 | 2003-09-25 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
EP1474103A1 (en) | 2002-02-15 | 2004-11-10 | King Pharmaceuticals, Inc. | Levothyroxine compositions and methods |
-
2001
- 2001-11-13 US US09/987,130 patent/US6645526B2/en not_active Expired - Lifetime
-
2002
- 2002-11-13 WO PCT/US2002/036266 patent/WO2003041700A1/en not_active Application Discontinuation
-
2003
- 2003-05-22 US US10/443,135 patent/US6936274B2/en not_active Expired - Lifetime
-
2005
- 2005-06-03 US US11/143,645 patent/US7195779B2/en not_active Expired - Lifetime
-
2007
- 2007-01-30 US US11/699,456 patent/US20070122476A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
US5635209A (en) | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
US5955105A (en) | 1995-11-14 | 1999-09-21 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
JP2002284679A (en) * | 2001-03-27 | 2002-10-03 | Teikoku Hormone Mfg Co Ltd | Stable solid preparation composition containing thyroid hormone |
Non-Patent Citations (1)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHITARA, KAZUHIRO ET AL: "Solid formulations containing thyroid hormone", XP002229153, retrieved from STN Database accession no. 137:268434 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2692340A1 (en) * | 2012-08-03 | 2014-02-05 | Verisfield (UK) Ltd. | Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof |
IT201700063186A1 (en) * | 2017-06-08 | 2018-12-08 | Trifarma S P A | PHARMACEUTICAL COMPOSITIONS OF LEVOTIROXINE SODIUM SALT |
Also Published As
Publication number | Publication date |
---|---|
US20030099698A1 (en) | 2003-05-29 |
US6645526B2 (en) | 2003-11-11 |
US20050232991A1 (en) | 2005-10-20 |
US7195779B2 (en) | 2007-03-27 |
US20040033259A1 (en) | 2004-02-19 |
US6936274B2 (en) | 2005-08-30 |
US20070122476A1 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6645526B2 (en) | Storage stable thyroxine active drug formulations and methods for their production | |
US20070196472A1 (en) | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions | |
US7052717B2 (en) | Storage stable thyroxine active drug formulations and methods for their production | |
JPH10194969A (en) | Tablet composition | |
US20070014854A1 (en) | Novel granulation process | |
KR20080083071A (en) | Pharmaceutical preparation containing nateglinide | |
US20070014864A1 (en) | Novel pharmaceutical granulate | |
HU224983B1 (en) | Swallow tablet comprising paracetamol | |
US20080125453A1 (en) | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions | |
US20180325852A1 (en) | Alditol-free, storage-stable thyroid hormone active drug formulations and methods for their production | |
KR100281521B1 (en) | Pharmaceutical Compositions Containing Sodium Pravastatin | |
US20070014853A1 (en) | Pharmaceutical dosage form containing novel pharmaceutical granulate | |
JPH0995447A (en) | Vitamin-containing composition | |
US8277840B2 (en) | Sustained release formulation of alprazolam | |
KR20070076388A (en) | Compression molded preparation | |
US9271951B2 (en) | Levothyroxine formulation with acacia | |
KR100594606B1 (en) | Immediate release medicinal compositions for oral use | |
JP3110299B2 (en) | Molded product and method for producing the same | |
KR100267525B1 (en) | Cytarabine ocfosfate hard capsule | |
US20050069584A1 (en) | Diphenhydramine tannate solid dose compositions and methods of use | |
US20140179784A1 (en) | Levothyroxine formulation with carrageenan | |
EP2941272A1 (en) | Levothyroxine formulation with acacia | |
EP1001773A1 (en) | Oral solid pharmaceutical compositions containing nicorandil for a modulated release and the process for their preparation | |
US20070249694A1 (en) | Metaxalone formulations and methods for the preparation thereof | |
WO2014098886A1 (en) | Levothyroxine formulation with carrageenan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |